- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03465579
Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging. (BIOPSTAGE)
Multi-cohort Investigational Study to Evaluate the Impact of Pelvic Mp-3TMRI and Whole-body 68Ga-PSMA PET/CT for Diagnosis of Clinically-significant Prostate Cancer and Pre-surgical Staging.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to characterize the diagnostic accuracy of both multi-parametric pelvic Magnetic Resonance Imaging (MRI) (T2-weighted, Diffusion Weighted Imaging (DWI), Dynamic Contrast Enhancement (DCE) and 68Ga-chelated Prostate Specific Membrane Antigen ligand (68Ga-PSMA) Positron Emission Tomography/Computed Tomography (PET /CT) in three cohorts of patients:
- COHORT 1 Guiding prostate biopsies in men with clinical suspicion and/or unconfirmed clinically-significant prostate cancer (CS-PCa) on initial prostate biopsy;
- COHORT 2 Targeting repeat prostate biopsy in patients on Active Surveillance (PRIAS Study), scheduled for PRIAS repeat biopsy;
- COHORT 3
Providing pelvic / whole-body pre-surgical staging in:
- 3a: men with high-risk PCa (HR-PCa);
- 3b: men candidates for nerve sparing surgery (NSS);
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Oriana Nanni
- Phone Number: +390543739266
- Email: oriana.nanni@irst.emr.it
Study Contact Backup
- Name: Federica Matteucci, MD
- Phone Number: +390543739100
- Email: federica.matteucci@irst.emr.it
Study Locations
-
-
FC
-
Forlì, FC, Italy, 47121
- Recruiting
- AUSL della Romagna
-
Contact:
- Roberta Gunelli
-
Meldola, FC, Italy, 47014
- Recruiting
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
-
Contact:
- Federica Matteucci, MD
- Phone Number: +390543739100
- Email: federica.matteucci@irst.emr.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Cohort 1 - Biopsy guidance in clinically-suspected PCa
1. Men aged 45 to 75 years old with clinically-suspected PCa candidated for either initial or repeat TRUS-guided prostate biopsy, meeting any of the following criteria:
a) Abnormal PSA metrics, defined as follows:
A rising and/or persistently elevated serum PSA (i.e PSA > 2.5ng/ml for men in the age group comprising 60 to 75 years old; PSA > 3.0ng/ml for men in the age group comprising 45 to 60 years old) and at least one of the following PSA-based metrics:
i. Percent free PSA (%fPSA) < 25% with PSA range 4-10ng/ml (NCCN); ii. PSA velocity (PSAvel) >0.35 ng/mL/y; iii. PSA density (PSAden) > 0.25ng/mL/cc iv. PSA > 10ng/ml, 50% risk of PCa (EAU) b) Suspicious digital rectal examination (DRE), 5-30% risk of PCa; c) Prostate Cancer Gene 3 (PCA3) > 35; d) Suspicious findings on first-round biopsy: i. A few Atypical Glands immediately adjacent to HG-PIN, 50% risk of PCa; ii. Atypical Small Acinar Proliferation, 40% of PCa; iii. Multifocal High-Grade Prostatic intraepithelial neoplasia (HG-PIN), 30% ; iv. Intraductal carcinoma as solitary finding, 90% of PCa;
Cohort 2 - Biopsy guidance on Active Surveillance
Men consenting to enter the PRIAS MRI side-study as per currently inclusion criteria in Version Number 1.0 dated August 20, 2013. These are:
- Histologically-proven adenocarcinoma of the prostate;
- Age ≥ 18
- Men should be fit for curative treatment;
- Clinical stage T1c or T2;
- Gleason score 3+3=6;
One or two biopsy cores invaded with prostate cancer:
- If an MRI, including targeted biopsies on positive lesions, is done at inclusion, there is no limit in the number of positive cores (that is, more than two, and no limit in the % of cancer present in the cores);
- If saturation biopsies (either trans-perineal or trans-rectal) are done 15% of the cores can be positive with a maximum of 4 (i.e. 26 cores 4 cores can be positive) (all other inclusion criteria still apply);
- PSA density (PSA D) less than 0.2;
- PSA-level at diagnosis ≤ 10 ng/mL;
Cohort 3a - Pre-surgical TNM staging in high-risk prostate cancer
- Male, aged 18 years or older;
- Cyto / histological confirmation of PCa (i.e. TRUS-guided biopsies; TURP);
Any of the PCa high risk features for Organ-Confined Disease (OCD):
- Clinical T stage ≥ T2c;
- Gleason Score ≥ 8;
- Serum PSA > 20 ng/mL;
Any of the PCa high-risk features for Locally-Advanced Disease (LAD):
- Clinical T stage ≥ T3b-T4 OR any T and clinical N1 disease;
- Gleason Score ≥ 8;
- Serum PSA > 20 ng/mL;
- Routine clinical staging (CTscan ± Bone scan) performed within 12 weeks enrolment returning negative or equivocal results for distant metastatic disease;
Cohort 3b - pelvic TNM staging of prostate cancer prior to nerve-sparing radical prostatectomy
- Male, aged 18 years or older;
- Cyto / histological confirmation of PCa (i.e. TRUS-guided biopsies; TURP);
All of the following PCa-related features must be met for nerve-sparing (either mono- or bi-lateral):
- Clinical T stage ≤ T2b;
- Gleason Score ≤ 7 (3+4) and maximum one biopsy with Gleason > 6 at the ipsilateral side;
- Serum PSA < 10 ng/mL;
Exclusion Criteria:
The participant may not enter the study if ANY of the following apply:
- Hormone androgen deprivation therapy of any type within 6 months prior to enrollment.
- Prior pelvic radiotherapy;
- Sickle cell disease;
- Insufficient renal function (eGFR < 30 mL/min/1.73 m2);
- Hip prosthesis, vascular grafting or other conditions affecting imaging;
- Contraindication to MRI, including but not restricted to: pacemaker or other electronic im-plants, known metal in the orbit, MR incompatible surgical or cerebral aneurysm clips, shrapnel, tattoos, non-removable body piercings (relative contraindications);
- History of allergic reactions attributed to compounds of similar chemical or biologic com-position to 68Ga-PSMA or Gadolinium-based contrast agents used in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Cohort 1
Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy
|
multi-parametric pelvic MRI
68Ga-PSMA PET/CT
|
Other: Cohort 2
Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.
|
multi-parametric pelvic MRI
68Ga-PSMA PET/CT
|
Other: Cohort 3a
Men with high-risk PCa (HR-PCa) prior to radical surgery.
|
multi-parametric pelvic MRI
68Ga-PSMA PET/CT
|
Other: Cohort 3b
Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).
|
multi-parametric pelvic MRI
68Ga-PSMA PET/CT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
sensitivity of both 68Ga-PSMA PET/CT and mp-3TMRI imaging
Time Frame: up to 36 months
|
sensitivity of both 68Ga-PSMA PET/CT and mp-3TMRI imaging will be calculated as the ratio between the number of positive cases at 68Ga-PSMA PET/CT or mp-3TMRI and number of patients who underwent to these exams
|
up to 36 months
|
specificity of both 68Ga-PSMA PET/CT and mp-3TMRI imaging
Time Frame: up to 36 months
|
specificity will be calculated considering negative cases at 68Ga-PSMA PET/CT or mp-3TMRI and number of patients who underwent to these exams
|
up to 36 months
|
Positive predictive value of both 68Ga-PSMA PET/CT and mp-3TMRI imaging
Time Frame: up to 36 months
|
Positive predictive value will be calculated considering the ratio between positive patient at 68Ga-PSMA PET/CT/mp-3TMRI confirmed as positive throughout biopsy and overall positive patient at 68Ga-PSMA PET/CT/mp-3TMRI
|
up to 36 months
|
negative predictive value of both 68Ga-PSMA PET/CT and mp-3TMRI imaging
Time Frame: up to 36 months
|
negative predictive value will be calculated considering the ratio between negative patient at 68Ga-PSMA PET/CT/mp-3TMRI confirmed as negative throughout biopsy and overall negative patient at 68Ga-PSMA PET/CT/mp-3TMRI
|
up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: up to 30 days following study procedures
|
The number and percentage of treated patients undergoing grade 1 to 4 adverse events will be tabulated for each cohort and diagnostic procedure, using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 should be used to assess and grade AE severity.
|
up to 30 days following study procedures
|
Collaborators and Investigators
Investigators
- Study Chair: Federica Matteucci, Irst Irccs
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Disease
- Molecular Mechanisms of Pharmacological Action
- Radiopharmaceuticals
- Gallium 68 PSMA-11
Other Study ID Numbers
- IRST185.05
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on pelvic MRI
-
Central Hospital, Nancy, FrancePfizerUnknownStructural Sacro-iliitisFrance
-
Shaare Zedek Medical CenterThe Hospital for Sick Children; Rambam Health Care Campus; Children's Hospital... and other collaboratorsCompleted
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
Centre Hospitalier Universitaire de BesanconUniversity Hospital, LilleUnknown
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...Completed
-
Royal Marsden NHS Foundation TrustPelican Cancer FoundationUnknownRectal Cancer | Rectal Neoplasms | Colonic PolypsUnited Kingdom
-
Case Comprehensive Cancer CenterWithdrawn
-
Assiut UniversityUnknownPelvic Floor Disorders
-
University Hospitals of North Midlands NHS TrustActive, not recruitingPelvic Floor DysfunctionUnited Kingdom
-
Assiut UniversityWithdrawn